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Background: Given the emerging role of microRNA in tumor disease progression, we investigated the association
between microRNA expression, liver metastasis and prognosis of colorectal cancer.
Methods: Colorectal cancer tissues from patients with or without liver metastases were profiled to identify
differentially expressed microRNA. Expression profile was further assessed using quantitative reverse transcription
PCR and in situ hybridization. Correlation between miR-181a expression, the most differentially expressed microRNA,
between patients with and without liver metastasis, and its downstream target genes were investigated using
qRT-PCR. Luciferase reporter assay was conducted to establish functional association between miR-181a and its
target genes. Manipulation of miR-181a expression and its consequences in tumor growth and metastasis were
demonstrated in various in vitro and in vivo models.
Results: miR-181a was revealed being the most elevated in CRC with liver metastases. miR-181a expression
correlated with advanced stage, distant metastasis, and served as an independent prognostic factor of poor overall
survival. Stable transfection of CRC cell lines with miR-181a promoted cell motility and invasion, as well as tumor
growth and liver metastasis,while silencing its expression resulted in reduced migration and invasion. Additionally,
we identified WIF-1 as direct and functional targets of miR-181a. Ectopic expression of miR-181a suppressed the
epithelial markers E-cadherin and β-catenin, while enhanced the mesenchymal markers vimentin.
Conclusion: Our data demonstrate that miR-181a expression is associated with CRC liver metastasis and survival.
miR-181a has strong tumor-promoting effects through inhibiting the expression of WIF-1, and its potential role in
promoting epithelial-mesenchymal transition.
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Colorectal cancer (CRC) is the third most prevalent can-
cer worldwide [1]. Approximately 50% of CRC patients
die from distant metastases, in particular liver metas-
tases. Most CRC patients with liver metastasis are not
candidates for surgical treatment, with 5-year survival
rate below 10% [2]. New diagnostic means to detect* Correspondence: zlguj@bjmu.edu.cn
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are in urgent demand.
microRNAs (miRNAs) are small, non-coding RNA
that silence specific target genes in mammalian cells by
repressing translation [3]. miRNAs play important roles
in tumor invasion and metastasis [4]. Depending on its
target genes, an miRNA can function either as an on-
cogene or a tumor suppressive gene [5]. Dysfunction of
miRNA is associated with CRC tumorigenesis and pro-
gression. Furthermore, aberrant expression of specific
miRNA may be used as potential prognostic and pre-
dictive markers in CRC [6-8]. However, more extensive
research is required to elucidate molecular mechanismshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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identify those miRNAs that may be employed as novel
prognostic predictors.
In the present study, microarray-based strategy was
applied to identify differentially expressed miRNA in
CRC by comparing miRNA profiles between colorectal
cancer tissues from patients with and without liver me-
tastases. miR-181a was most significantly up-regulated
in cancerous tissues with liver metastasis compared to
without liver metastasis. Its tumor promoting function
and mechanism were further characterized.
Results
miRNAs are differentially expressed in CRC tumor tissues
from patients with or without liver metastasis
To investigate the role of miRNA in CRC liver metasta-
sis, miRNA expression was profiled in CRC tumor tissue
from patients with (n = 5) or without (n = 5) liver metas-
tases. Among the 743 miRNA probes on Mammalian
miRNA arrayV2.0, 214 miRNAs were detected in CRC
tissues. hsa-miR-181a was detected to be most elevated
with > 2-fold between CRC with and without liver me-
tastasis. (Additional file 1: Table S1).
The microarray results were validated with quantita-
tive reverse transcription PCR (qRT-PCR) by confirming
the expression of hsa-miR-181a in the same 10 human
CRC tissues. All further analyses in this study focused
on miR-181a.
Deregulated expression of miR-181a is associated with
liver metastasis in CRC patients
To verify the microarray results of differentiated miRNA
expression, we performed qRT-PCR analyses in a cohort
of 137 paired CRC and normal tissues (Validation Co-
hort 1).
qRT-PCR analysis revealed a significant increase in
miR-181a expression in tumor tissue (n = 137) compared
with matched adjacent normal tissues (n = 137, fold
change: 2.46, p = 0.0002). We then analyzed the relation-
ship between miR-181a expression and liver metastasis.
The relative expression ratio of miR-181a to U6 in pa-
tients with synchronous liver metastasis (n = 63) is sig-
nificantly higher than those without metastasis (n = 60,
fold change: 2.56, p = 0.0003). In addition, its expression
in patients with metachronous liver metastasis (n = 14)
is remarkably higher than those without metastasis (fold
change: 1.93, p = 0.0114). These data demonstrate that
miR-181a expression is elevated in CRC tumor tissues
compared to surrounding normal tissue, and this ele-
vated expression level of miR-181a correlates with liver
metastasis in CRC patients (Figure 1).
Given that miR-181a is part of a family that includes
miR-181a-d, we also checked the expression of three
other miR-181 family members, miR-181b, miR-181cand miR-181d, to see whether they were also associated
with metastases. Our results show that miR-181b-d ex-
pressions are not associated with CRC liver metastasis
(Figure 1G-I). These results suggest that the association
of miR-181a with CRC metastases is specific. The miR-
Base accession number and the mature sequence of the
microRNAs studied are available in Additional file 1:
Table S2.
Elevated miR-181a expression correlates with advanced
clinical stage, distant metastasis, and serves as an
independent prognosis factor of poor survival
The clinical significance of miR-181a up regulation in
CRC was further investigated in Validation Cohort 1. The
expression of miR-181a increased remarkably with the
advanced CRC TNM stages. Elevated miR-181a expres-
sion was significantly correlated with local tumor invasion
(T stage), lymph node metastases or liver metastases, but
not with other clinical-pathological parameters (Table 1,
Figure 1C-E). Kaplan-Meier analysis showed that high
miR-181a expression (above the median value in this 137
patient cohort) was associated with poor overall survival
in CRC (Figure 1F). These results suggested that the up
regulation of miR-181a may play an important role in the
development and progression of CRC.
Furthermore, multivariate analysis was performed to
determine the prognostic value of miR-181a expression
using the Cox proportional hazard model. The risk vari-
ables examined included miR-181a expression level, as
well as factors known to significantly affect the outcome
of CRC such as age and gender of patients, diffe-
rentiation, lymph node metastasis, surgical-pathological
staging, histological type and venous invasion. In the
univariate analysis, high miR-181a expression level in
tumors (HR 2.22; 95% CI 1.307 to 3.77; p = 0.003), TNM
staging (HR 11.057; 95% CI 3.995 to 30.605; p < 0.0001),
venous invasion (HR 2.462; 95% CI 1.476 to 4.108;
p = 0.001), and lymph node metastasis (HR 4.27; 95% CI
2.156 to 8.454; p < 0.0001) were significantly associated
with survival; while age, gender, differentiation and
histological type were not (Table 2). In the final multi-
variate Cox regression model, high miR-181a expression
in tumors was associated with a poor survival prognosis
(HR 1.871; 95% CI 1.078 to 3.246; p = 0.026) independ-
ent of other clinical covariates (Table 2).
miR-181a localizes in colorectal epithelial cells and serves
as an independent prognostic marker of CRC overall
survival
To further elucidate the functional role of miR-181a in
CRC, we utilized in situ hybridization (ISH) to study the
expression pattern of miR-181a in tumor and corre-
sponding non-tumor tissue. A high level expression of
miR-181a was detected in epithelial cells with elevated
Figure 1 Association between miR-181a expression in tumors and overall survival in CRC using qRT-PCR. (A) The levels of miR-181a in
137 CRC tissues (Validation Cohort 1) were significantly higher than those in matched adjacent normal tissues; (B) The levels of miR-181a were
significantly higher in patients with synchronous (PSLM) and metachronous liver metastasis (PMLM) than those without liver metastasis (PNM);
(C-E) The expression levels of miR-181a were positively correlated with advanced TNM stages, T stage and N stage. Expression of miR-181a was
presented in log10 scale and was normalised against an endogenous reference U6; (F) Kaplan-Meier overall survival curves for CRC patients were
compared according to miR-181a expression level. Patients with higher miR-181a expression displayed a shorter overall survival after surgery.
(G-I) The expressions of miR-181b-d in 21 paired CRC patients with and without liver metastasis by qPCR.
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In cancerous tissue, miR-181a expression was detected
only in the cytoplasm of tumor cells but not in tumor
stroma, consistent with its role in tumor cells during
colorectal carcinogenesis. Low levels of miR-181a ex-
pression were also seen in normal mucosa (Figure 2). To
assess whether miR-181a expression is correlated with
miR-181a ISH score, we assayed miR-181a expression by
qPCR in 30 fresh CRC samples frozen in liquid nitrogen
that were matched to the samples used for ISH. Our re-
sults showed that miR-181a expression was correlated
with miR-181a ISH score (Figure 2H).
Expression of miR-181a was characterized in Validation
Cohort 2, micro tissue arrays consisting of tumor samples
from 294 CRC patients with different liver metastasis sta-
tus, e.g., none, synchronous or metachronous liver metas-
tasis to further validate the association between miR-181a
expression and liver metastasis. Consistent with qRT-PCRresults derived from Validation Cohort 1, miR-181a was
significant less frequently expressed in PNLM (16/97,
16.5%) and normal tissue (14/72, 19.4%) than in PSLM
(63/160, 39.4%) and PMLM (22/37, 59.5%) (p < 0.001).
Moreover, elevated miR-181a expression in tumor tissue
detected by ISH was significantly associated with poor
survival (p < 0.001) (Figure 2G). In univariate analysis of
Validation Cohort 2, high expression of miR-181a in
tumor tissue (HR 1.514; 95% CI 1.223 to 1.874; p < 0.001),
TNM staging (HR 6.509; 95% CI 4.02 to 10.54; p < 0.001),
venous invasion (HR 2.375; 95% CI 1.758 to 3.21;
p < 0.001), differentiation (HR 0.438; 95% CI 0.224 to
0.858; p = 0.016) and lymphnode metastasis (HR 2.916;
95% CI 2.062 to 4.125; p < 0.001) were significantly asso-
ciated with survival; while age, gender, and histological
type were not. In the final multivariate Cox regression
model, high miR-181a expression in tumor tissue was as-
sociated with a poor survival prognosis (HR 1.382; 95% CI
Table 1 Relationship between miR-181a expression and pathological features in CRC patients
miR-181a expression (RQ: 2 − ΔCt)
Variable Case no. Median Range p
Gender 0.646
Male 77 0.002267 0.00028409-0.086144702
Female 60 0.002338 0.000051016-0.016974115
Age 0.118
≤60(median) 64 0.0026165970 0.000051016-0.040007408
>60 73 0.0018319950 0.000215355-0.086144702
Venous invasion 0.18
Positive 50 0.002491 0.000473623-0.086144702
Negative 87 0.002013 0.000051016-0.017423945
T stage < 0.0001
T1 1 0.0003546
T2 12 0.000522 0.000215-0.002013
T3 102 0.002697 0.000051-0.0635
T4 22 0.003080 0.000286-0.08614
N stage 0.0362
N0 55 0.001813 0.000215-0.0635
N1 40 0.002767 0.000286-0.08615
N2 42 0.002537 0.000051-0.01697
M stage 0.0023
M0 74 0.002008 0.000051-0.01697
M1 63 0.003277 0.000606-0.08615
TNM stage < 0.0001
I 12 0.0004145 0.000215-0.002013
П 33 0.002306 0.000421-0.01586
III 29 0.002267 0.000051-0.01697
IV 63 0.002653 0.000353-0.08615
Differentiation 0.4114
Poor 32 0.002538 0.000051-0.01577
Moderate 76 0.002425 0.000266-0.08615
Well 29 0.001738 0.000233-0.04001
Histological type
Adenocarcinoma 130 0.002339 0.000215-0.08615 0.5348
Mucinous adenocarcinoma 7 0.001962 0.000051-0.006384
Quantified by stem–loop-based qRT–PCR. miR-181a was normalized to U6. Mann–Whitney test for the comparison between two groups or Kruskal–Walis test for
more groups.
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variates consistent with results derived from Validation
Cohort 1 (Table 2).
miR-181a promotes CRC cell growth, invasion and liver
metastasis
To explore the potential mechanism of miR-181a in pro-
moting CRC progression, HT29 CRC cells were infected
with pri-miR-181a lentivirus to determine its effects on
cell growth in vitro and in vivo. Stable expression of miR-181a was confirmed using quantitative PCR (Figure 3A).
Elevated miR-181a expression results in stimulated cell
growth in culture (Figure 3B). Consistent with in-vitro
results, the tumor growth curves showed that the
growth of lentiviral miR-181a HT29 tumors was mar-
kedly increased compared with tumors derived from
parental cell line HT-29, and lentiviral empty vector-
infected cells (HT29-NC). Elevated miR-181a expres-
sion in HT29 CRC cells stimulated tumor growth in
NOD-SCID mice resulting in increased tumor weight
Table 2 Univariate and multivariate Cox regression analysis of miR-181a expression levels and overall cancer survival in subjects with colorectal cancer
Cohort 1 Cohort 2
Characteristic Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) P Value HR (95% CI) PValue HR (95% CI) PValue HR (95% CI) P Value
miR-181a expression 2.22 (1.307-3.77) 0.003 1.871 (1.078-3.246) 0.026 1.514 (1.223-1.874) <0.001 1.382 (1.11-1.721) 0.004
High
Low
Gender 0.714 (0.423-1.206) 0.208 1.119 (0.650-1.927) 0.685 1.141 (0.845-1.54) 0.39 1.001 (0.734-1.366) 0.995
Male
Female
Age 1.034 (0.621-1.723) 0.898 1.023 (0.600-1.743) 1.075 (0.795-1.453) 0.637 1.147 (0.839-1.569) 0.389
≤60 (median) 0.935
>60
Venous invasion 2.462 (1.476-4.108) 0.001 1.243 (0.709-2.179) 0.447 2.375 (1.758-3.21) <0.001 1.593 (1.15-2.207) 0.005
Positive
Negative
TNM stage 11.057 (3.995-30.605) <0.0001 30.732 (8.165-115.679) <0.0001 6.509 (4.02-10.54) <0.001 8.363 (4.414-15.846) <0.001
I-П
III- IV
Histological type 0.927 (0.290-2.966) 0.899 0.550 (0.148-2.043) 0.372 0.913 (0.428-1.945) 0.813 0.806 (0.354-1.836) 0.608
Adenocarcinoma
Mucinous adenocarcinoma
Lymph node metastasis 4.27 (2.156-8.454) <0.0001 3.578 (1.417-9.033) 0.007 2.916 (2.062-4.125) <0.001 1.686 (1.075-2.645) 0.023
Positive
Negative


















Figure 2 miRNA detection in colorectal cancer tissues by
LNA-ISH. In situ hybridization analyses using 5′ DIG-labeled,
LNA-modified DNA probes complementary to miR-181a, U6 small
nuclear RNA and scrambled oligonucleotide (negative control) were
performed on tissue microarray sections. (A) The expression of
miR-181a was negative or weak in most of the normal colorectal
mucosa; (B) Negative expression of miR-181a was also detected in
some colorectal cancer tissues; (C) The weak positive expression of
miR-181a was detected in the cytoplasm of cancer cells (+); (D) The
strong positive expression of miR-181a was detected in the cytoplasm
of cancer cells (2+); (E) No signal was detected in colorectal cancer
tissues by using scrambled oligonucleotide probe (negative control);
(F) The nuclear expression of U6 (positive control); (G) Association
between miR-181a expression in tumors and overall survival in 294
patients with CRC using in situ hybridisation (cohort 2). Kaplan-Meier
overall survival curves for CRC patients with follow-up information were
compared according to miR-181a expression level. Patients with higher
miR-181a expression displayed a shorter overall survival after surgery.
(H) Association between miR-181a expression in CRC tumors and
miR-181a ISH score. The levels of miR-181a detected by qPCR in 30
sample tissues that are matched to the samples used for ISH.
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0.10 g (HT29) (p < 0.05) (Figure 3C).
The effect of miR-181a on tumor invasion and metastasis
was assessed. Cell wound healing assay showed that ele-
vated miR-181a expression significantly enhanced tumor
cell mobility in HT29-181a cells compared with HT29-NC
or the parental HT 29 cells (p = 0.004) (Figure 3D). Fur-
thermore, the ability of cell migration and cell invasion
through matrigel were significantly enhanced by overex-
pressing miR-181a in HT29 cells (HT29-181a) compared
with controls (HT29-NC and HT29) as demonstrated in
Boyden Chamber assays (migration 2.74-fold, p = 0.03,
invasion 34.7-fold, p = 0.049 respectively) (Figure 3E).
The migration and invasion through matrigel of lenti–
miR-181a-infected SW480 cells were dramatically en-
hance by 3.75-fold (p = 0.0008) and 4.67-fold (p = 0.0003)
respectively, compared with controls (Figure 3G). A
wound-healing assay revealed that the spreading of lenti–
miR-181a-infected SW480 cells into the wound was much
faster than the control cells (p = 0.0083) (Figure 3F). These
results indicate that miR-181a stimulates colorectal cancer
cell spreading, migration and invasion, suggesting its
potential role in cancer metastasis.
The promoting effect of miR-181a on liver metastasis
was demonstrated applying an experimental metastasis
model by injecting HT29 overexpressing miR-181a cells
into mouse spleens. HT29 cells with elevated miR-181a
expression resulted in increased number of liver meta-
static nodules as compared to that induced by HT29
cells transfected with control vector or the parental
HT29 cells with average liver surface metastatic nodules
of 6 ± 1.6; 2.4 ± 1.3; 1.2 ± 1.3 for HT29-181a, HT29-NC,
and HT29 respectively (p < 0.05) (Figure 3H).
Figure 3 (See legend on next page.)
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Figure 3 Ectopic expression of miR-181a enhanced CRC cell in vitro migration and invasion as well as in vivo liver metastasis. (A) The
expression of miR-181a/b normalized to U6 was assayed in pri-miR-181a lentivirus infected HT-29 cells (HT29-181a), HT29 cells infected with control
vector (HT29-NC) and parental HT29 cells (HT29). The data represent fold changes in miRNA expression. The limits of the 95% confidence intervals
indicate variability of the changes; (B) Cell growth rates were stimulated by miR-181a in HT29 cells detected by CCK-8 assay. (C) The effect of miR-181a
on the growth of HT-29 cells was evaluated in NOD-SCID mice. (C-1) Tumour growth curves. Points and bars represent the mean tumor volume with
SD, eight mice in each group, p < 0.05; (C-2) Tumor weight derived from HT-29 cells expression different levels of miR-181a; (C-3) Tumors derived from
HT-29 cells expression different levels of miR-181a; (D) Wound-healing assay shows that cell motility was enhanced following miR-181a over-expression
in HT29 cells. D-1) Representative images from wounds made using a confluent monolayer of HT-29, HT29-NC and HT29-181a cells taken at 0 h and
48 h post wounding, imaged using IncuCyte ZOOM. D-2) The quantification results of cell motility (wound confluence) are plotted. Data represent the
mean ± SD of three independent experiments. (E) Boyden chamber assays were performed with and without matrigel. The quantification results of
migrated cells and invaded cells through Matrigel are plotted in (E-2) and (E-3), respectively. Data represent the mean ± SD of three independent
experiments with six random fields counted for each chamber; (F) Wound-healing assay shows that cell motility was enhanced following miR-181a
over-expression in SW480 cells. (G) Cell migration and invasion were significantly enhanced in SW480 overexpressing miR-181a cells. (H) miR-181a
enhances HT-29 cells liver metastasis. Representative livers derived from NOD-SCID mice are shown.
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the role of miR-181a in promoting tumor metastasis
consistent with its clinical association with liver metasta-
ses in CRC patients.
miR-181a targets the 3′-UTR of tumor suppressor
gene WIF-1
To elucidate the biological mechanisms underlying the
role of miR-181a in promoting tumor cell growth and
metastasis, we investigated the potential targets of miR-
181a. Target prediction programs, miRanda and TargetS-
can, were applied to identify WIF-1 as putative miR-181a
target. The 3′-UTR of WIF-1 mRNA contains a comple-
mentary site for the seed region of miR-181a (Figure 4A).
To verify this finding, WIF-1 3′-UTRs and its mutant con-
taining the putative miR-181a binding sites were cloned
downstream of the luciferase open reading frame. These
reporter constructs were co-transfected into HEK293T
cells with either miR-SC or miR-181a mimics. Increased
expression of miR-181a upon infection of miR-181a mi-
mics, significantly suppressed luciferase expression derived
from reporter constructs containing wild type WIF-1
3′-UTRs with inhibition rates 40% (p < 0.05) comparing to
cells co-transfected with miR-SC. This suppressive effect
was abolished when mutated 3′-UTR of WIF-1 mRNAs,
in which the binding sites for miR-181a were inactivated
by site-directed mutagenesis, were co-infected with miR-
181a (Figure 4B). These results support WIF-1 as putative
target of miR-181a.
Functional regulation of WIF-1 expression by miR-181a
was further analyzed by modulating miR-181a levels via
overexpression or knockdown in three CRC cell lines,
HT29, SW480 and SW620. WIF-1 mRNA levels were
substantially suppressed in HT29 overexpressing miR-
181a and SW480 overexpressing miR-181a cells as com-
pared with that in control cells (Figure 4C, E). Meanwhile,
the protein levels of WIF-1 were also suppressed afterectopic overexpression of miR-181a in HT29 and SW480
cell lines (Figure 4F, G). On the other hand, knock down
of miR-181a via RNA interference in HT29 andSW620
cells resulted in increased mRNA and protein levels of
WIF-1 (Figure 4C-G).
Collectively, these data support the bioinformatics pre-
diction of WIF-1 as direct targets of miR-181a and
established a functional association.
Knockdown of miR-181a suppresses tumour growth and
metastasis
To confirm further the tumour-promoting function of
miR-181a, we infected the highly metastatic cell line
SW620 with miR-181a-RNAi lentivirus and measured its
effects on cell spreading, migration and invasion in vitro.
Consistent with the results of over-expressing miR-181a
in HT-29 cells, the inhibition of miR-181a in SW620 cells
remarkably decreased the cell motility (p = 0.02) and cell
invasion through matrigel (p = 0.03), as demonstrated by
Boyden chamber assays (Figure 5A). A wound-healing
assay revealed that the spreading of lenti–miR-181a-RNAi
infected SW620 cells into the wound was much slower
than the control cells (Figure 5B).
Knockdown of WIF-1 enhances tumour growth and
metastasis
To explore the biological functions of WIF-1 in CRC
cells, we determined whether inhibition of WIF-1 pro-
moted CRC cell migration and invasion. In HT-29 cells,
in vitro knockdown of WIF-1 promoted cell migration
(p < 0.0001) and cell invasion (p = 0.0018) (Figure 5C).
To further test this, we transfected SW620-181a-RNAi
cells with siRNA for WIF-1 mRNA and found that the
effect of miR-181a RNAi was partially attenuated by
siRNA for WIF-1 mRNA (Figure 5D-E). These data con-
firmed that the prometastasis effect of miR-181a was
mediated by inhibiting target genes WIF-1.
Figure 4 (See legend on next page.)
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Figure 4 WIF-1 is target of miR-181a. (A) Schematic illustration of the predicted miR-181a-binding sites in WIF-1 3′-UTR; (B) Luciferase reporter
assay demonstrates that miR-181a inhibited the wild-type, but not the mutant, 3′-UTRs of WIF-1 reporter activities compared with the vector alone
control. The data represent the mean ± SD of three independent experiments with quadruplicates of sample. Student’ s t-test, * p < 0.05 versus control
(wild-type 3 -UTR reporter vector +miR scramble) or mutant 3-UTR reporter group (mutant 3 -UTR reporter +miR-181a mimics/miR scramble); (C) The
expression of endogenous WIF-1 was inhibited in the pool of lenti-pri-181a-infected HT29 cells and enhanced in lenti-pri-181a-RNAi-infected HT29 cells,
compared with the control, at mRNA level as detected by qRT-PCR; bar, mRNA expression normalized to GAPDH mRNA; (D, E) WIF-1 mRNA levels
were substantially enhanced in lenti-pri-181a-RNAi-infected SW620 (D) and suppressed in SW480 overexpressing miR-181a cells(E), compared with
the controls; (F, G) Western blot results show that the proteins of WIF-1 were down-regulated following lenti–pri–181a infection and up-regulated
following lenti-pri-181a-RNAi infection (F, HT29 cell; G, SW620 and SW480cells). β-Actin served as an internal loading control. (H, I) The statistical
analysis results of ratio of WIF1 compared to β-actin (H, HT29 cell; I-1, SW620; I-2, SW480 cells). Data represent the mean ± SD of three
independent experiments.
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protein expression of WIF-1 in CRC tissues
The regulation of WIF-1 mRNA expression by miR-181a
was further characterized in Validation Cohort 1 of 137
primary CRC tissues using qRT-PCR. A significant in-
verse correlation between the levels of miR-181a and
mRNA expression of WIF-1 was confirmed with Pearson
correlation = −0.5291; and p < 0.0001 (Figure 6A).
The protein expression of WIF-1 was also examined in
paired CRC and normal tissues by Western Blot analysis.
A significant decrease in WIF-1 expression was seen in
tumor tissues compared with the matched adjacent nor-
mal tissue (Figure 6B), while their miR-181a expressions
were shown an inverse trend (Figure 6C). The same in-
verse correlation was further demonstrated when protein
expression of WIF-1 was examined in Validation Cohort
2 of TMA. High levels of miR-181a in tumor cells corre-
lated with low levels of WIF-1 protein expression. Con-
versely, low levels of miR-181a in adjacent normal tissue
correlated with high levels of WIF-1 protein expression
(Figure 6D). We also investigated the prognostic signifi-
cance of WIF-1 in CRC Cohort 2, Kaplan-Meier analysis
was performed illustrating that low WIF-1 expression
was associated with poorer overall survival in the CRC
cohort 2(p = 0.004, Figure 6E).
Overexpression of miR-181a induces epithelial-
mesenchymal transition (EMT) in CRC
The cell morphology of the stable SW480 hsa-miR-
181a–overexpressing cell line was significantly altered;
the cells had long and thin processes, cell-to-cell contact
was reduced. The cell morphology of the miR-181a-
knockdown SW620 was also altered, and the cell-to-cell
contaction was increased (Figure 7A).
When miR-181a was overexpressed in SW480 cells, two
epithelial markers, E-cadherin and β-catenin, were sup-
pressed; while the mesenchymal marker, vimentin, was in-
duced. On the other hand, knockdown of miR-181a in
SW620 cells induced E-cadherin and β-catenin expression
and suppressed vimentin expression (Figure 7B). Con-
sistent results were also obtained when these CRC cells
expressing different levels of miR-181a were examinedwith immunofluorescence staining (Figure 7C). We also
assessed the epithelial and mesenchymal markers in HT29
overexpressing miR-181a cells. The results are consistent
with results derived from SW480 cells (Figure 7B). We ex-
amined the effect of WIF1 on EMT in HT29 cell lines.
The expression levels of E-cadherin and β-catenin were
decreased; while vimentin was increased in HT29-WIF-1
siRNA cells (Figure 7B).
Taken together, these results suggest that elevated
miR-181a levels in CRC may be involved in inducing
EMT and therefore further promoting invasion and
metastasis.
Discussion
Recent studies have demonstrated that miRNA play im-
portant roles in tumor invasion and metastasis. In this
study, miRNA profiles between five colorectal cancer tis-
sues with synchronous liver metastases and five colorectal
cancer tissues without liver metastases were compared.
miR-181a demonstrated overexpression in colorectal can-
cer with liver metastasis.
Following microarray, we validated the deregulated
miRNAs in two cohorts. We observed that up regulation
of miR-181a is a frequent event in CRC tissues. High-
level expression of miR-181a was significantly associated
with colorectal cancer liver metastasis and especially
with metachronous liver metastasis. Due to the largest
absolute fold change, miR-181a was chosen for further
study. The up regulation miR-181a was significantly as-
sociated with advanced clinical stage, distant metastasis
and poorer overall survival in CRC.
Our results are similar with Nishimura’s report [9]. It is
reported that high miR-181a expression group had a sig-
nificantly poorer prognosis. High miR-181a expression
was an independent significant prognostic factor for CRC.
However, in Nishimura’s report, they did not find miR-
181a to be differentially expressed between the normal
colon and colorectal cancer tissue, nor did they see any as-
sociations between miR-181a and any clinicopathological
parameters investigated. In the present study, qRT-PCR
and ISH analysis revealed a significant increase in miR-
181a expression in tumor tissue compared with matched
Figure 5 Knockdown of miR-181a suppresses SW620 cell in vitro migration and invasion. Prometastasis effect of miR-181a is mediated by
inhibiting target genes WIF-1. (A-1) Cell migration and invasion through matrigel were significantly suppressed in miR-181a knockdown SW620
cells compared with the controls, as demonstrated by a Boyden chamber assay without matrigel or with matrigel. (A-2, A-3)The quantification
results of migrated cells and invaded cells through matrigel are plotted in (A-2) and (A-3), respectively. Results are displayed as the mean ± SD of
three independent experiments with six random fields counted for each chamber. ∗Student’s t-test. (B-1) Wound-healing assay shows that cell
motility was inhibited following miR-181a knockdown. (B-2) The quantification results of cell motility (wound confluence) are plotted. Data represent the
mean ± SD of three independent experiments. (C) Knockdown of WIF-1 by siRNA in HT29 cells significantly promoted cell migration and invasion
through matrigel. Representative fields of migration cells and invaded cells through matrigel on the membrane (C-1). Average number of migration cells
(C-2) and invaded cells (C-3) number per field from three independent experiments ± standard error (right). (D-E) SW620-181a-RNAi cells transfected with
WIF-1 siRNA or a negative control (NC) siRNA. (D-1, D-2, D-3) Cell migration and invasion through matrigel assay with WIF-1 siRNA reversing miR-181a
knockdown-mediated suppression of cell migration and invasion. (E-1) Western blot analysis for WIF-1 showing levels of WIF-1. (E-2) The statistical
analysis results of ratio of WIF1 compared to β-actin. Data represent the mean ± SD of three independent experiments.
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associated with the different normal tissues origin and
number in two studies. We think the difference of sample
cohort’s composition, especially the clinical stage distribu-
tion and the proportion of liver metastasis samples results
in different analysis in the correlations between miR-181a
expression and clinicopathological parameters.
The role of miR-181a in cancer development is com-
plicated. For instance, some studies demonstrated that it
is up-regulated in pancreatic cancer and breast cancer
[10,11]. However, different groups showed that miR-181a was down-regulated in gliomas [12] and aggressive
CLL. [13] Several studies have shown that miR-181 fa-
mily members were up-regulated in hepatocellular can-
cer stem cells [14,15].
In this study, the effects of miR-181a on CRC deve-
lopment and progression were also investigated by both
in-vitro and in-vivo assays. Overexpression of miR-181a
could effectively promote CRC cell growth rate, migration
and invasion in vitro and tumor growth and liver metasta-
sis in vivo, whereas knockdown of miR-181a expression
reduced CRC cell migration and invasion.
Figure 6 miR-181a levels are inversely correlated with WIF-1 expression in CRC tissues. (A) The relationship between miR-181a expression
and WIF-1 mRNA levels in CRC samples (90 cases). Statistically significant reverse correlations were observed between miR-181a and WIF-1 mRNA levels
with the use of two-tailed Spearman’s test; (B) Western blot results show that the proteins expression level of WIF-1 is lower in tumor tissue (T ) than
normal adjacent tissues (N). (C) The levels of miR-181a in above 8 pairs of sample tissues. (D) Expression patterns of WIF-1 immunohistochemistry in
tissue microarrays of Cohort 2. The expression of WIF1 proteins in adjacent non-malignant mucosa (A), and CRC tissues with low (B) and high (C) WIF1
protein expression. Positive cells are stained brown. (E) Association between WIF1 expression in tumors and overall survival in 294 patients with CRC
using immunohistochemistry (cohort 2). Kaplan-Meier overall survival curves for CRC patients with follow-up information were compared according to
WIF1 expression level. Patients with lower WIF1 expression displayed a shorter overall survival after surgery.
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role in the invasive and/or metastatic potential of CRC.
Each miRNA can potentially downregulate many tar-
get genes through binding their 3′-UTR. One important
task is to identify the downstream target genes regulated
by the dysregulated miRNA. In the present study, quan-
titative PCR and western blot analysis demonstrated that
miR-181a could decrease the expression of WIF-1 in
both mRNA and protein levels. In addition, inhibiting
miR-181a expression could increase WIF-1 expression.
Luciferase assay showed that miR-181a could interact
with the 3′-UTR of WIF-1. We also found that knock-
down of WIF-1 gene expression by siRNA reversed
miR-181a-RNAi-mediated suppression of tumor cell
migration. Moreover, the expression of WIF-1 was
negatively correlated with miR-181a in clinical CRC
specimens. These observations indicate that miR-181amechanistically acts via the regulation of WIF-1. Our re-
sults also showed that low-level expression of WIF-1 is
positively correlated with tumor metastasis and/or poor
prognosis. This is consistent with our finding that up
regulation of miR-181a is associated with CRC liver me-
tastasis and poorer overall survival.
WIF-1, Wnt inhibitory factor-1, is a secreted antagon-
ist that can bind to Wnt proteins directly and inhibit
Wnt signaling pathway. It has been reported that WIF-1
expression is down regulated in several human cancer
including prostate, bladder, breast, nonsmall-cell lung
carcinomas and colorectal cancer [16-18]. Several groups
have reported that restoring WIF-1 expression in cancer
cells could inhibit cancer cell growth [19,20]. Our re-
sults, along with the roles of WIF-1 in tumor progres-
sion, indicate the involvement of the miR-181a-WIF-1
regulation chain in CRC progression.
Figure 7 (See legend on next page.)
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Figure 7 Overexpression of miR-181a induces CRC cell epithelial mesenchymal transition. (A) The morphology of SW480 and SW620 CRC
cells with miR-181a overexpression or knockdown. The cell-to-cell contact was reduced in hsa-miR-181a–overexpressing SW480 cells and increased in
miR-181a knockdown SW620 cells compared with the controls. (B) Expression of epithelial and mesenchymal markers were compared by Western blot
analysis between miR-control-SW480 and miR-181a-SW480 cells, between miR-control-SW620 and miR-181a-RNAi-SW620 cells, between miR-control-
HT29 and miR-181a-HT29 cells, between HT29-NC and HT29-WIF1-siRNA cells. β-actin was used as a loading control; (C) Immunofluorescence was used
to compare the expression levels and pattern of epithelial and mesenchymal markers between miR-control-SW480 and miR-181a-SW480 cells, between
miR-control-SW620 and miR-181a-RNAi-SW620 cells. Epithelial markers (E-cadherinand β-catenin, red signal) were down-regulated in miR-181a-SW480
cells and up-regulated in miR-181a-RNAi-SW620 cells; mesenchymal markers (vimentin, red signal) were up-regulated in miR-181a-SW480 cells and
down-regulated in miR-181a-RNAi-SW620 cells.
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kinase (NLK), an inhibitor of wnt/β-catenin signaling in
Hepatocellular cancer [15]. We speculate that miR-181a
could affect colorectal cancer cells EMT. EMT appears
to be a key event in tumor invasion and metastasis
[21,22]. Thus, epithelial cells lose their epithelial adher-
ence and tight junction proteins, lose their polarity and
cell-cell contact, and undergo remarkable remodeling of
the cytoskeleton, all of which facilitates cell motility and
invasion. In present study, we found that the overex-
pression of miR-181a induces EMT, as shown by the de-
creased expression of the epithelial markers E-cadherin
and β-catenin, and enhanced expression of the mesen-
chymal markers vimentin.
These findings suggest that miR-181a plays a critical
role in regulating epithelial-emesenchymal cell transition
and, ultimately, promotes the invasive and/or metastatic
potential of CRC, probably by its direct target on WIF-1
gene. We further assessed whether the miR-181a in-
duced EMT is due to the direct regulation of WIF1. We
found that inhibition of WIF1 could lead to EMT in
HT29 cell line, which suggesting that the miR-181a in-
duced EMT is due to the direct regulation of WIF1.
In summary, we demonstrated in this study that the
higher expression of miR-181a in CRC specimens is as-
sociated with liver metastasis and poor survival, and in
particular, the higher expression of miR-181a is associ-
ated with metachronous liver metastasis. In this study,
we also investigated the potential role of miR-181a in
CRC liver metastasis and its underlying mechanisms.
Our data suggest that up regulation of miR-181a plays
an important role in CRC cell metastasis, and that
the tumor-promoting function of miR-181a is through
repressing its downstream target gene WIF-1. miR-181a
could be employed as a new prognostic marker and/or as
an effective therapeutic target for CRC.
Materials and methods
Cell line and experimental animals
Human CRC cell lines HT29, SW480 and SW620 were
purchased from American Type Culture Collection and
were maintained in Dulbecco’s Modified Eagle medium
(Gibco, Carlsbad, CA) with 10% fetal bovine serum, 100 U/ml penicillin sodium and 100 mg/ml streptomycin sulfate
in humidified 5% CO2 at 37°C. Male NOD-SCID mice (4–6
weeks old) were purchased from Beijing HFK Bio-
technology Co. Ltd. (Beijing, China). Mice were maintained
in a pathogen-free facility and used in accordance with the
institutional guidelines for animal care.
Patients and samples
CRC samples were collected from surgical resection at
Peking University Cancer Hospital & Institute (Beijing,
China). All samples were immediately frozen in liquid ni-
trogen and stored at −80°C or fixed in 10% formalin for
paraffin embedding. Samples collection and usage in the
present study were approved by the Ethics Review Commit-
tees of Peking University Cancer Hospital & Institute.
The Testing Cohort consisted of CRC tumor specimens
from patients with synchronous liver metastases (n = 5) or
without (n = 5) liver metastases (follow up > 6 years). Sam-
ples were analyzed using microarray to generate differen-
tial miRNA profiling between CRC tumor tissues with and
without liver metastases. Validation Cohort 1 consisting of
fresh CRC and surrounding non-tumor tissue were ob-
tained from 137 patients who underwent surgical resec-
tions from 2001 to 2006. These samples were analyzed by
quantitative reverse transcription PCR (qRT-PCR). Valid-
ation Cohort 2, independent from Validation Cohort 1,
consisting of CRC and surrounding non-tumor tissues
were obtained from 294 patients who underwent surgical
resections from 1999 to 2006. These samples were paraf-
fin-embedded and micro-dissected to generate tissue
microarrays (TMAs) for in situ hybridization (ISH) and
immunohistochemstry. All samples were collected from
patients prior to receiving any preoperative chemotherapy
or radiotherapy, and were verified to contain at least 80%
tumor cells. Cases with familial adenomatous polyposis
CRC were excluded from the study. Final cut off date of
follow-up was January 30, 2012. All samples have follow-
up data. A summary of the clinical characteristics of these
patients is shown in Additional file 1: Table S3 and S4.
RNA isolation and miRNA profiling
Total RNA was extracted from 5 CRC tissues with and 5
without liver metastases using TRIZOL reagent (Invitrogen)
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array profiling was performed at CapitalBio Corporation
(Beijing, China) following standard procedures detailed on
http://www.capitalbio.com. Fluorescein-labeled miRNA
were used for hybridization on Mammalian miRNA
arrayV2.0 (CapitalBio, Beijing, China) containing 743 probes
in triplicate, corresponding to 576 human miRNAs (includ-
ing 122 predicted miRNAs). Hybridization signals were de-
tected and arrays were scanned with a LuxScanTM 10 K/A
laser confocal scanner (CapitalBio, Beijing, China). The raw
pixel intensities were extracted using the LuxScan3.0 soft-
ware (CapitalBio, Beijing, China). The data were normalized
between slides using the quantile normalization method
proposed by Bolstad et al. [23]. The differentially expressed
genes, classified as those with Fold changes above 2, were
selected using the SAM software, version 2.1.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using miRNeasy Mini Kit
(Qiagen, Hilden, Germany). For miRNA quantification,
the miRNAs levels were assayed using TaqMan MicroRNA
assays, according to the manufacturer’s protocol (Applied
Biosystems, Carlsbad, CA). The u6 small nuclear B non-
coding RNA (RNU6B, Applied Biosystems, Carlsbad, CA)
level was used as an internal normalization control.
For mRNA detection, total RNA (2 μg) was used in 20 μl
of reverse transcriptase reaction to synthesize cDNA by
using Moloney murine leukemia virus reverse transcriptase
(M-MLV RT) for RT-PCR (Invitrogen, Carlsbad, CA),
according to the manufacturer’s protocol. Real-time PCR
was performed using the above RT products with the SYBR
Green PCR Master Mix (Toyobo Co. Ltd., Osaka, Japan)
on an ABI7500 PCR machine. PCR cycling conditions were:
95°C for 1 minute, 40 cycles of 95°C for 15 seconds, 60°C
for 15 seconds and 72°C for 45 seconds. Data are presented
as relative quantification (RQ) to U6 or GAPDH based on
calculations of 2-ΔCt where ΔCt =Ct(Target)-Ct(Reference), or as
ΔCt. Fold changes were calculated by the 2-ΔΔCt. All
primers are listed in Additional file 1: Table S5.
Tissue microarrays
Paraffin-embedded samples were microdissected and tis-
sue microarrays (TMAs) were constructed in quadrupli-
cates using a previously described method [24]. Seven
TMAs were constructed to include 160 Primary CRC tu-
mors with Synchronous Liver Metastasis (PSLM), 97 Pri-
mary CRC tumors with Non-Liver Metastasis (PNLM),
37 Primary CRC tumors with metachronous liver metas-
tasis (PMLM), and 72 paired adjacent normal colorectal
mucosa and 32 matched liver metastasis tissues.
In situ hybridization analysis
Digoxigenin (DIG)-labeled mercury locked nucleic acid
probes for human miR-181a, U6 (positive control) andscramble DNA (negative control) were purchased from
TaKaRa (Dalian, China). The in situ hybridization (ISH)
was performed with a modified version of the protocol
for formalin-fixed paraffin-embedded tissue by Wigard
Kloosterman (http://www.exiqon.com/ls/Documents/Scien-
tific/FFPE%20in%20situ%20hybridization.pdf ) on human
colorectal cancer tissues. The sequence and hybridization
temperature of probes were showed in Additional file 1:
Table S5.
The slides were then scored by two pathologists inde-
pendently as negative (−), weak or focally positive (1+),
or strongly positive (2+) [25]. Both pathologists were
blinded to the patient’s clinical outcome.
Oligonucleotide, lentiviral vector construction and cell
infection
miRNA mimics, the miRNA inhibitor and negative con-
trol miRNA oligonucleotides of has-miR-181a were from
RiboBio Co. Ltd (Guangzhou, China). The small inter-
fering RNAs (siRNAs) targeting WIF-1 were synthesized
by RiboBio Co. Ltd. An unrelated sequence was used as a
negative control (provided by RiboBio). The sequence was
WIF1 siRNA, 5′ GAGUACUCAUAGGAUUUGA dTdT -3′
(sense). Stable transfectants overexpressing or knockdown
miR-181a were generated by lentiviral transduction using
a pGCsil-GFP vector (GeneChem Co., Ltd, Shanghai,
China). A lentiviral vector expressing green fluorescent
protein alone (LV-GFP) was used as a control. Trans-
fection of oligonucleotides or lentivirus construction was
performed using the Lipofectamine 2000 reagent (Invitro-
gen) according to the manufacturer’s instructions. HT-29,
SW480 and SW620 cells were infected with recombi-
nant lentivirus-transducing units plus 8 μg/ml Polybrene
(Sigma, St Louis, Missouri, USA).
In vitro cell growth, spreading, motility and invasion
assays
Cell growth was assessed using CCK-8 (Dojindo, Tokyo,
Japan) according to the manufacturer’s instructions.
Cell spreading was evaluated by a wound healing
assay. The wound healing assay was performed by the
CellPlayer™ 96-Well Kinetic Cell Migration assay (The
Essen BioScience IncuCyteTM Live-Cell Imaging System).
Cells were seeded into 96-well plate and cultured until
attached. The woundMaker™ and wounding procedure
were used to create precise and reproducible wounds in
all wells of the 96-well plate. The plate was placed into
the IncuCyte™ ZOOM to scan every hour for migration
assays. The data was analyzed by wound confluence,
Wound confluence (%) represents the fractional area of
the wound that is occupied by cells.
Cell motility or invasion was measured using a Boyden
chamber assay with or without Matrigel. Photographs of
three randomly selected fields of the fixed cells were
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peated three times independently. These assays were
carried out as previously described [26].
In vivo tumor growth and liver metastasis assay
For the tumorigenecity study, HT29 cells, has-miR-
181a-expressing cells (HT29-181a+) and empty vector
cells (HT29-NC) were injected subcutaneously into the
back of NOD-SCID mice (8 mice/group). Over a 4-week
period, tumor formation in mice was observed by mea-
suring the tumor volume calculated by the formula
V = 0.5xLxW2. Tumors were then excised and weighed.
HT29 cells, has-miR-181a-expressing cells (HT29-
181a+) and empty vector cells (HT29-NC) were assayed
for metastasis in 5- to 6-week-old NOD-SCID mice
using the splenic injection model as described previously
[27]. Cells (1 × 106) were injected into the spleen subcap-
sular through an abdominal incision under sterile con-
ditions. After injection, the spleen was returned gently
back to abdominal cavity and homoeostasis was assured.
The area was thoroughly irrigated with warm sterile
water and the abdominal cavity was closed in appropri-
ate layers. Ten weeks after surgery, mice were eutha-
nized and the livers were obtained to determine the liver
weight and hepatic metastatic foci.
All animal experiments were reviewed and approved by
the Ethics Review Committee at the Peking University
School of Oncology.
Luciferase reporter assay
The 3′-UTR of WIF-1 was amplified via polymerase
chain reaction (PCR) from human genomic DNA con-
structed and cloned into pmiR-RB-REPORT™Luciferase,
downstream of the firefly luciferase gene to form pMIR-
3′-UTR WIF-1 and pMIR-3′-UTR WIF-1-Mut con-
structs (primers are listed in Additional file 1: Table S3).
For the luciferase assay, HEK 293 T cells were seeded in
96-well plates, pMIR-3′-UTR constructs were co-trans-
fected with miR-181a mimics or miR scramble (miR-SC)
(50 nM, synthesized by Ribobio Co. Guangzhou, China)
using the Lipofectamine2000 method. The activities of
firefly luciferase and Renilla luciferase were measured at
24 h post-transfection using the dual-luciferase reporter
assay kit (Promega) following the manufacturer’s protocol.
Firefly luciferase activity was normalized to that of the
Renilla luciferase for each sample. Each experimental
group consisted of three wells and the experiment was re-
peated three times.
Western blot analysis
Total protein lysates extracted from samples were quanti-
tated using BCA protein assay kit (Pierce, Rockford, IL).
20 μg total protein lysates extracted from samples were
separated with 10% sodium dodecyl sulfate-polyacryl-amide gels and transferred to a polyvinylidene fluoride-
membrane. The membrane was blocked with 3% BSA,
followed by incubation with mouse monoclonal anti-hu-
man WIF-1 (Abcam, Cambridge, MA), rabbit polyclonal
anti-human E-cadherin, β-catenin and vimentin (Cell
Signaling Technology Inc., Danvers, MA), anti-human
β-Actin antibody (Epitomics, Burlingame, CA). The mem-
brane was then incubated with secondary horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse anti-
body (Jackson Immune Research Laboratories Inc., West
Grove, PA), and visualized using Immobilon™ Western
Chemiluminescent HRP substrate (Millipore). β-Actin was
used as the loading control.Immunohistochemical analysis on Tissue Microarray
(TMA)
Immunohistochemical studies of WIF-1 were done on
tissue microarray using the Polymer Detection System
for immune-histological staining (PV9000 kit, ZSJQ-Bio,
China). All images were examined by two experienced
pathologists independently. Immunostaining was eva-
luated as described [28] previous.Immunofluorescence analysis
SW480, SW480-NC, SW480-181a, SW620, SW620-NC,
SW620-181a RNAi cells were plated in a 96-well mi-
croplate and were cultured overnight until cells were
adherent. Cells were fixed and stained with anti-E-
cadherin, −β-catenin and-vimentin primary antibody
and DyLight549 Goat Anti-rabbit Secondary Antibody.
Cells were also labeled with Hoechst 33342 Dye for
nuclear staining. Expression of E-cadherin, β-catenin
and vimentin was imaged using a laser scanning con-
focal microscopy (TCS-SP2, Leica Microsystems).Statistical analysis
All data are presented as the mean ± standard error (SE)
and were analyzed using the statistical package SPSS13.0.
Data are expressed as median values (interquartile range)
in supplementary tables or as means ± SE in the figures.
Comparisons were performed using the nonparametric
Mann–Whitney U test or Kruskal-Walis test for con-
tinuous variables. Spearman’s rho correlation test (two
tailed) was used to estimate the correlation between the
expression in CRC tissue of each marker and clinical-
pathological variables. Survival curves were plotted using
the Kaplan-Meier analysis and the log-rank test was used
to test for significant differences. Cox univariate and
multivariate proportional hazard models were used to esti-
mate the hazard ratio for each marker. P ≤ 0.05 was con-
sidered statistically significant.
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